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Background: A growing body of evidence suggests that diabetes is a risk factor for endometrial cancer incidence. However, most
of these studies used case-control study designs and did not adjust for obesity, an established risk factor for endometrial cancer.
In addition, few epidemiological studies have examined the association between diabetes treatment and endometrial cancer risk.
The objective of this study was to assess the relationships among diabetes, diabetes treatment and endometrial cancer risk in
postmenopausal women participating in the Women’s Health Initiative (WHI).
Methods: A total of 88 107 postmenopausal women aged 50–79 years who were free of cancer and had no hysterectomy at
baseline were followed until date of endometrial cancer diagnosis, death, hysterectomy or loss to follow-up, whichever came first.
Endometrial cancers were confirmed by central medical record and pathology report review. Multivariate Cox proportional
hazards regression models were used to estimate hazard ratios (HRs) (95% confidence interval (CI)) for diagnosis of diabetes and
metformin treatment as risk factors for endometrial cancer.
Results: Over a mean of 11 years of follow-up, 1241 endometrial cancers developed. In the primary analysis that focused on
prevalent diabetes at enrolment, compared with women without diabetes, women with self-reported diabetes, and the subset of
women with treated diabetes, had significantly higher risk of endometrial cancer without adjusting for BMI (HR¼ 1.44, 95% CI:
1.13–1.85 for diabetes, HR¼ 1.57, 95% CI: 1.19–2.07 for treated diabetes). However after adjusting for BMI, the associations
between diabetes, diabetes treatment, diabetes duration and the risk of endometrial cancer became non-significant. Elevated risk
was noted when considering combining diabetes diagnosed at baseline and during follow-up as time-dependent exposure
(HR¼ 1.31, 95% CI: 1.08–1.59) even after adjusting for BMI. No significant association was observed between metformin use and
endometrial cancer risk.
Conclusions: Our results suggest that the relationship observed in previous research between diabetes and endometrial cancer
incidence may be largely confounded by body weight, although some modest independent elevated risk remains.
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Endometrial cancer is the most common gynaecologic cancer in
the US women (Fader et al, 2009; ACS, 2013), and its incidence
and mortality rose between 2006–2010 (Howlader et al, 2013).
Obesity is one major risk factor for endometrial cancer (Kaaks
et al, 2002; Renehan et al, 2008; Crosbie et al, 2010). Other
consistently reported risk factors for endometrial cancer include
reproductive factors, physical inactivity and hypertension (Purdie
and Green, 2001; Dossus et al, 2010). The main hypothesis that has
been proposed to explain endometrial carcinogenesis is that
exposure of the endometrium to excess oestrogen unopposed by
progesterone increases the mitogenic activity of endometrial cells
(Key and Pike, 1988). This hypothesis has been supported by
epidemiologic studies showing that an increased risk of endometrial
cancer is associated with use of unopposed exogenous estrogens
(Smith et al, 1975; Ziel and Finkle, 1975; Grady et al, 1995; Crosbie
et al, 2010).
A growing body of evidence suggests that diabetes may be
another risk factor for endometrial cancer (Friberg et al, 2007b).
A meta-analysis of 13 studies published in 2007 (Friberg et al, 2007b)
and a more recent meta-analysis (Zhang et al, 2013) of prospective
studies reported an increased risk of endometrial cancer associated
with diabetes. Insulin resistance and hyperinsulinemia have also
been linked to an increased risk of endometrial cancer (Gunter
et al, 2008; Mu et al, 2012). Given the adverse effect of obesity on
the incidence of both diabetes and endometrial cancer, it is
important to adjust for obesity when examining the independent
association of diabetes on endometrial cancer risk. However,
among a total of eight cohort studies examining diabetes associated
with incidence of endometrial cancer, only three studies (Terry
et al, 1999; Anderson et al, 2001; Friberg et al, 2007a) adjusted for
body mass index (BMI) with one study (Friberg et al, 2007a)
reporting a significant association independent of BMI. Thus, more
large prospective studies are needed to examine whether the
association between diabetes and endometrial cancer is partly or
largely accounted for by obesity.
Metformin is a biguanide that has been used worldwide for the
management of type 2 diabetes. It improves glycemic control by
enhancing insulin sensitivity (Cusi and DeFronzo, 1998). Evidence
from epidemiologic, clinical and experimental research has
suggested that metformin may have potential anticancer effects
(Evans et al, 2005; Buzzai et al, 2007; Ben Sahra et al, 2008; Decensi
et al, 2010; Noto et al, 2012). The potential role of metformin as an
anti-neoplastic agent for endometrial cancer has been explored in a
number of in vitro and in vivo studies (Cantrell et al, 2010; Tan
et al, 2011; Xie et al, 2011; Zhang et al, 2011). However, to the best
of our knowledge, there is only one case-control study examining
the association between metformin treatment and endometrial
cancer risk, and the findings were null (Becker et al, 2013).
In this study, we used the Women’s Health Initiative (WHI), a
large, prospective cohort study, to examine the relationship among
diabetes, metformin treatment and endometrial cancer risk. We
tested the hypotheses that diabetes is associated with increased risk
of endometrial cancer controlling for obesity and other covariates,
and that metformin has a protective effect in reducing endometrial
cancer risk.
MATERIALS AND METHODS
Women’s Health Initiative. The WHI was designed to address
the major causes of morbidity and mortality in postmenopausal
women (1998), including both multi-center clinical trials (CT) and
an observational study (OS). Details of the scientific rationale,
eligibility requirements and baseline characteristics of the partici-
pants in the WHI have been published elsewhere (Hays et al, 2003;
Jackson et al, 2003; Langer et al, 2003; Ritenbaugh et al, 2003;
Stefanick et al, 2003). Briefly, a total of 161 808 women ages 50–79
were recruited at 40 clinical centers throughout the United States
between 1 September, 1993 and 31 December 1998. The WHI CT
includes four overlapping components: two Hormone Therapy
Trials (27 347 women), a Dietary Modification Trial (48 835
women) and a Calcium/Vitamin D Supplementation Trial (36 282
women). Participants in the OS included 93 676 women who were
screened for the CT but were ineligible or unwilling to participate,
or were recruited through a direct invitation for the OS. The study
was overseen by institutional review boards at all 40 clinical centers
and at the coordinating center, as well as by a study-wide data and
safety-monitoring board. All participants in WHI gave informed
signed consent and were followed prospectively.
The following participants were excluded from the original
cohort of 161 808 for this analysis: 12 655 women who had a
history of cancer (except non-melanoma skin cancer) at baseline;
792 women who joined but provided no follow-up information;
60 016 who had had a hysterectomy, 129 women who were
diagnosed with diabetes before age 20 and/or who were ever
hospitalised for diabetic coma (these were deemed to have a
probable type 1 diabetes diagnosis); and 109 women who had
missing values of the main exposures (including diagnosis of
diabetes, age at diagnosis and diabetes treatment). After exclusions,
88 107 women remained for further analysis.
Measurement of exposures, outcome and confounders
Exposures. Diabetes, diabetes treatment and diabetes duration at
baseline were used as primary exposures. Prevalence of diabetes at
enrolment was defined by a positive answer to the question: ‘did a
doctor ever say that you had sugar diabetes or high blood sugar
when you were not pregnant’, or by reported use of medication to
treat diabetes collected on the study medication inventory. Treated
diabetes at enrolment was defined as yes or no if the participant
reported ever having been treated or not for diabetes with pills or
insulin shots. Information on the type of treatment for diabetes
was extracted from the WHI medication inventory collected at
baseline; diabetic patients were divided into three groups based on
the type of drugs used currently (i.e., metformin, insulin or others).
The duration of diabetes at enrolment was based on the difference
between age of participants when first diagnosed with diabetes and
age at enrolment.
Incidence of medically treated diabetes was also determined
during annual WHI follow-up. The definition of incident diabetes
was a positive response to the question: ‘since the date given on this
form has a doctor prescribed any of the following pills or
treatments?’, and mention of any newly prescribed pills for treating
diabetes, or insulin shots, on either the semi-annual or annual
follow-up questionnaires. Self-reported diabetes in WHI has been
validated by medication inventories, laboratory data and chart
review as a reliable indicator of diagnosed diabetes (Margolis et al,
2008; Jackson et al, 2013).
Follow-up and ascertainment of cases. Incident endometrial
cancer cases were identified by self-administered questionnaires
(administered every 6 months in the CT through 2005, and
annually in the CT after 2005 and in the OS), with all cases
confirmed by medical record review. All primary endometrial
cancer cases were then coded centrally in accordance with the
Surveillance Epidemiology and End Results (SEER) coding guide-
lines. For these analyses participants were followed to first
endometrial cancer diagnosis, date of hysterectomy, date of death,
loss to follow-up or end of CT or OS follow-up (30 September,
2010), whichever occurred first.
Confounders. In the multivariable models, we considered a series
of potential confounders, including age at enrolment (o55, 55–59,
60–64, 65–69, 70–74, X75), ethnicity (American Indian or Alaska
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Native, Asian or Pacific Islander, Black or African-American,
Hispanic/Latino, non-Hispanic white and other), education (high
school or less, some college/technical training, college or some
post-college and master or higher), smoking status (never,
former—including years since quitting: X30, 20–29, 10–19, o10
and current–including cigarettes smoked per day: o5, 5–14,
15–24,X25), recreational physical activity (total metabolic equivalent
tasks (METs) per week: o5, 5—o10, 10–o20, 20–o30, X30),
alcohol intake (non-drinker, past drinker, o1 drink per month
and current drinker—including frequency:o1 drink per month, 1
drink per month to o1 drink per week, 1–o7 drinks per week,
X7 drinks per week) and history of Hormone Therapy use (none,
oestrogen alone, oestrogen and progestin, mixed), oral contra-
ception use, parity (never pregnant, never had term pregnancy, 1,
2, 3, 4,X5), age at menarche (o12, 12–13, 14–15,X16 years); age
at first live birth (never had term pregnancy,o20 years, 20–29;
X30 years), family history of endometrial cancer.
Indices of obesity were included in multivariate models also, to
better evaluate the independent effects of the exposure on the
outcome: these included body mass index (o18.5, 18.5–24.9,
25.0–29.9, 30.0–34.9, 35.0–39.9, X40).
Statistical analysis. For the distribution of demographic char-
acteristics by diabetes status, w2 tests were used to evaluate
differences for categorical covariates, and t-tests were used for
continuous variables. Cox proportional hazards regression models
were employed to estimate hazard ratios (HRs) and 95%
confidence intervals (CIs) for the association between diabetes
and risk of endometrial cancer. In the multivariable models, we
adjusted for age, ethnicity, education, smoking status, BMI, waist-
to-hip ratio, alcohol consumption, physical activity, and history of
Hormone Therapy use, oral contraception use, parity, age at
menarche, age at first live birth and family history of endometrial
cancer as described above. Different study cohorts (participation in
OS or CTs, and different treatment assignments for all three
clinical trials) were treated as strata in the model to take into
account possible different baseline hazards in different sub-groups
and treatment effects.
The effect of exposure was examined in different ways. The first
set of analyses was focused on prevalent diabetes as an exposure
(4247 women with prevalent diabetes), including diabetes status,
treatment of diabetes and duration of prevalent diabetes at
enrolment. In the second set of analyses, we considered all treated
diabetes as an exposure, including prevalent and incident-treated
diabetes newly occurring during WHI follow-up (10046 women
had or developed diabetes). In all analyses including incident
diabetes, a time-dependent covariate was generated by taking into
account change in diabetes status during follow-up. That is, we
considered women in the non-diabetes group until they reported
diabetes.
In addition, we also performed stratified analysis by obesity.
Interaction between diabetes and obesity was tested by entering
cross-product terms into the multiplicative models. The propor-
tionality assumption was satisfied for all exposure variables of
interest and potential confounding variables based on graphs of
scaled Schoenfeld residuals (Hess, 1995). All statistical analyses
were conducted using SAS (Version 9.3, SAS Institute, Cary,
NC, USA).
RESULTS
Baseline characteristics by type 2 diabetes status at enrolment are
shown in Table 1. Compared with women without diabetes,
women with diabetes were more likely to be older, non-White
(non-Hispanic), less educated, and have higher BMI and higher
waist-to-hip ratio. They were less physically active, and were more
likely to be a non-drinker, report a family history of endometrial
cancer, have hypertension, have younger age at menarche, have
younger age at first birth and have greater number of term
pregnancies. Women with diabetes were also less likely to report a
history of oral contraception use or oestrogen plus progestin
hormone therapy use (all P-values o0.05). Among 4247 (4.8%)
diabetic women, 39.1% were receiving no pharmacologic treatment
for diabetes, 12.5% used metformin, 31.9% used other oral
medications and 16.5% used insulin (Table 1).
Over a mean of 11 years of follow-up, 1241 endometrial cancers
developed. In the primary analysis, self-reported diabetes at
enrolment was significantly associated with risk of endometrial
cancer in the age-adjusted model and the multivariable-adjusted
model without including BMI (Figure 1, Table 2). The association
became weaker and non-significant after further adjusting for BMI
in the multivariable-adjusted model (HR¼ 1.16, 95% CI: 0.90–1.48)
(Table 2). Similar results were found for women with treated
diabetes, women who used metformin alone, women who received
insulin and women with long duration (X6 years) of diabetes.
These significant associations were observed only without adjust-
ing for BMI, but not in the multivariable-adjusted model that
adjusted for BMI. Similar patterns were observed in data stratified
by BMI (o30 kgm 2 or X30 kgm 2), but no significant
association was observed for women with diabetes regardless of
the type of treatment for diabetes or duration of diabetes (Table 3).
While adjusting for BMI that also attenuated the risk of
endometrial cancer, it remained significantly elevated when
combining treated diabetes at baseline and incident-treated
diabetes diagnosed during follow-up as a time-dependent exposure
(Table 4, HR¼ 1.31, 95% CI: 1.08–1.59). Similar finding were
noted regardless of the duration of diabetes and for women treated
with oral medications (HR¼ 1.33, 95% CI: 1.07–1.65). However,
we did not observe significantly elevated endometrial cancer risk
after adjustment for BMI in the smaller subsets of women treated
with insulin, metformin or other drugs regimens. In addition, we
compared endometrial cancer risk in metformin users and all non-
metformin users in analyses restricted to diabetic women and
found HR¼ 1.00 (95% CI: 0.62–1.62) without adjusting for BMI
and HR¼ 0.97 (95% CI: 0.60–1.58) with adjusting for BMI in the
time-dependent diabetes status model (data not shown).
We did a sensitivity analysis by excluding the first 2 years of
follow-up and found that the results were similar to the primary
analysis. For example, the HR for endometrial cancer was 1.44
(95% CI: 1.10–1.89) in women with prevalent diabetes without
adjusting for BMI, and the HR dropped to 1.14 (95% CI: 0.87–1.49)
after adjusting for BMI. We did another sensitivity analysis
by restricting the analysis to endometrioid adenocarcinoma
(938 cases) and found similar results as the findings when treating
endometrial cancer cases as a whole (data not shown).
DISCUSSION
In this large prospective study of postmenopausal women, our
findings suggest that the relationship between diabetes and
endometrial cancer incidence may be largely explained by body
weight. There may, however, be a modest independent relationship
between treated diabetes and endometrial cancer, as suggested by
the analyses that include the larger number of cases among women
with either prevalent or incident diabetes. In addition, our data
did not support a protective role of metformin in endometrial
cancer risk.
Obesity is an established risk factor for endometrial cancer (Kaaks
et al, 2002; Renehan et al, 2008; Crosbie et al, 2010). Due to the close
relation between obesity and diabetes, it is important to control for
the confounding (in the sense of common cause) effect of BMI when
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examining the relationship between diabetes and risk of endometrial
cancer. A few studies have examined the effect modification
of diabetes and endometrial cancer by body weight. However,
the findings of these studies have been inconsistent. A case-control
study (Saltzman et al, 2008) reported that diabetes was associated
with endometrial cancer among women with a BMI less than
Table 1. Baseline characteristics of participants by diabetes status among 88 107 women at Women’s Health Initiative enrolmenta
Variable No diabetes diabetes P-value
Total number of women 83 860 (95.2) 4247 (4.8)
Age at baseline (mean, years) 62.9 64.4 o0.0001
White, non-Hispanic ethnicity (%) 71 714 (85.5) 2910 (68.5) o0.0001
College graduate or above education (%) 37 100 (44.2) 1343 (31.6) o0.0001
Body mass index (mean, kgm 2) 27.4 31.9 o0.0001
Underweight (o18.5) 894 (1.1) 20 (0.5)
Normal (18.5–24.9) 31 649 (38.1) 628 (14.9)
Overweight (25.0–29.9) 28 756 (34.6) 1165 (27.6)
Obesity I (30.0–34.9) 13 874 (16.7) 1185 (28.1)
Obesity II (35.0–39.9) 5294 (6.4) 718 (17.0)
Extreme obesity (X40) 2628 (3.2) 502 (11.9)
Waist-to-hip ratio 0.80 0.87 o0.0001
Physical activity (mean, METsb per week 13.2 9.5 o0.0001
Smoking status 0.2
Never smokers 41 846 (49.9) 2140 (50.4)
Former smokers 35 145 (41.9) 1760 (41.4)
Current smokers 5811 (6.9) 266 (6.3)
Alcohol intake o0.0001
Non-drinker 8166 (9.7) 720 (17.0)
Past drinker 13 043 (15.6) 1552 (36.5)
Current drinker 62 073 (74.0) 1921 (45.2)
Family history of endometrial cancer (%) 4133 (4.9) 259 (6.1) o0.0001
History of hypertension (yes, %) 23 281 (27.8) 2574 (60.6) o0.0001
Age at menarche o0.0001
Less than 12 years old 8998 (10.7) 633 (14.9)
12–13 years old 32 965 (39.3) 1638 (38.6)
14–15 years old 18 862 (22.5) 774 (18.2)
16 years or old 10 151 (12.1) 474 (11.2)
Age at first birth o0.0001
o20 8000 (9.5) 586 (13.8)
20–29 49 839 (59.4) 2191 (51.6)
30þ 7343 (8.8) 377 (8.9)
Number of term pregnancies o0.0001
Never pregnant 8351 (10.0) 423 (10.0)
Never had term pregnancy 2315 (2.8) 101 (2.4)
1 7293 (8.7) 376 (8.9)
2 21 204 (25.3) 843 (19.9)
3 20 179 (24.1) 907 (21.4)
4 12 403 (14.8) 701 (16.5)
5þ 11 586 (13.8) 858 (20.2)
Oral contraception use (yes, %) 35 959 (42.9) 1501 (35.3) o0.0001
History of hormone therapy use o0.0001
None 44 928 (53.6) 2886 (68.0)
Oestrogen alone 5828 (7.0) 306 (7.2)
Oestrogen and progestin 29 029 (34.6) 935 (22.0)
Mixed 4075 (4.9) 120 (2.8)
Type of diabetic drugs in medication inventory
Untreated/drugs unknown 1662 (39.1)
Metformin alone Not available 529 (12.5)
Other oral medication alone Not available 1355 (31.9)
Insulin (alone or with oral medication) Not available 701 (16.5)
aSome of categories did not exactly sum up to the total number, because of missing values.
bMET¼metabolic equivalent task.
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35 kgm 2 but not among women with a BMI of 35 kgm 2 or more,
while another case-control study (Lucenteforte et al, 2007) reported
that the association with diabetes was stronger for obese women
compared with non-obese ones. Our stratified analysis by obesity
status revealed no significant association between diabetes and
endometrial cancer in either the obese or non-obese group, although
the patterns in both groups were similar to the overall data.
Our data indicate that the relationship between diabetes and
endometrial cancer incidence may be largely confounded by body
weight, but did not rule out completely some independent
association between newly diagnosed diabetes and endometrial
cancer. We observed non-significant increased risk of endometrial
cancer associated with prevalent diabetes and significant increased
risk associated with combined prevalent and incident diabetes. One
explanation for the difference may be due to increased study power
when using combined prevalent and incident diabetes. Another
possible explanation may be related to higher level of circulating
insulin (hyperinsulinemia) in a recent diagnosis of diabetes than a
more distant diagnosis. This hypothesis was supported by a study
(Saltzman et al, 2008) that observed a significant association
between diabetes and risk of endometrial cancer only among
women with a recent diabetes diagnosis (o5 years) but not among
those with a more distant diagnosis, although the same finding was
not observed in our data. It is biologically plausible that diagnosed
diabetes is associated with endometrial cancer risk. High levels of
insulin have been found to exert direct and indirect effects that
contribute to the development of endometrial cancer. Insulin can
promote tumorigenesis through a direct effect on epithelial tissues
acting on the insulin/insulin-like growth factor family of receptors
(Belfiore et al, 2009), or indirectly by affecting the levels of other
modulations, such as insulin-like growth factors, sex hormones and
adipokines (Pollak et al, 2004; Wolf et al, 2005).
Laboratory models provide impressive evidence for the activity of
metformin in endometrial cancer treatment and chemoprevention
P =0.01
0.00
0.01
0.01
0.01
0.02
0.03
4247 3748 2222 97Diabetes
83 860 77 750 57 775 3002No diabetes
Number at risk
0 5 10 15 20
Non-diabetes 
Diabetes
Nelson–Aalen cumulative hazard estimates
Survival time (year)
Figure 1. Cumulative hazard estimates (unadjusted) of endometrial
cancer by diabetes status at baseline.
Table 2. Hazard ratios and 95% confidence intervals for endometrial cancer incidence associated with diabetes status and treatment of diabetes at
baseline
Exposure
Endometrial
cancer cases
Person-
years
Incidence
rate (per
1000)
Age-adjusted
hazard ratio
(95% confidence
interval)
Multiple-adjusted
hazard ratio
(95% confidence
interval)a
Multiple-adjusted
hazard ratio
(95% confidence
interval)b
Diabetesc
No 1170 936 312 1.25 1 1 1
Yes 71 41 952 1.69 1.33 (1.05–1.69) 1.44 (1.13–1.85) 1.16 (0.90–1.48)
Treated diabetesc
No 16 11 319 1.41 1.11 (0.68–1.81) 1.14 (0.70–1.87) 0.95 (0.58–1.57)
Yes 55 30 772 1.79 1.41 (1.08–1.85) 1.57 (1.19–2.07) 1.23 (0.93–1.63)
Pill only 38 21 895 1.74 1.36 (0.99–1.88) 1.51 (1.09–2.10) 1.20 (0.86–1.66)
Insulin (alone or with oral medication) 17 8877 1.92 1.52 (0.94–2.45) 1.71 (1.05–2.77) 1.33 (0.82–2.16)
Type of diabetic drugs in medication inventory
Untreated/drugs unknown 30 16 891 1.78 1.40 (0.97–2.00) 1.47 (1.02–2.12) 1.23 (0.85–1.77)
Metformin alone 12 4996 2.40 1.88 (1.07–3.32) 2.11 (1.19–3.74) 1.64 (0.92–2.91)
Other oral medication alone 15 13 404 1.12 0.88 (0.53–1.46) 0.97 (0.58–1.62) 0.76 (0.45–1.27)
Insulin (alone or with oral medication) 14 6661 2.10 1.67 (0.99–2.83) 1.85 (1.09–3.15) 1.41 (0.83–2.41)
Duration of diabetesc
o6 years 30 20 757 1.45 1.14 (0.80–1.64) 1.23 (0.86–1.78) 0.96 (0.66–1.39)
X6 years 41 21 195 1.93 1.51 (1.11–2.07) 1.65 (1.21–2.27) 1.36 (0.99–1.87)
aIn multivariable models, we adjusted for age at enrolment (o55, 55–59, 60–64, 65–69, 70–74, X75), ethnicity (American Indian or Alaska Native, Asian or Pacific Islander, Black or African-
American, Hispanic/Latino, non-Hispanic white and other), education (high school or less, some college/technical training, college or some post-college and master or higher), smoking status
(never, former, current), recreational physical activity (total metabolic equivalent tasks (METs) per week:o5, 5–o10, 10–o20, 20–o30,X30), alcohol intake (non-drinker, past drinker,o1 drink
per month and current drinker—including frequency:o1 drink per month, 1 drink per month too1 drink per week, 1 too7 drinks/ per week,47 drinks per week), history of hormone therapy
use (none, oestrogen alone, oestrogen and progestin, mixed), parity (never pregnant, never had term, age of menarche (less than 12, 12–13, 14–15,X16 years), age at first birth (never had term
pregnant, o20, 20–29, X30 years), oral contraception use and different treatment assignments for clinical trials.
bAdditionally adjusted for body mass index (o18.5, 18.5–24.9, 25.0–29.9, 30.0–34.9, 35.0–39.9, 440).
cDiabetes, treated diabetes and diabetes duration in the table were based on baseline data. Diabetes at enrolment was defined by a positive answer to the question: ‘did a doctor ever say that
you had sugar diabetes or high blood sugar when you were not pregnant’, or by reported use of medication to treat diabetes collected on the study medication inventory. Treated diabetes at
enrolment was defined as yes or no if the participant reported ever having been treated or not for diabetes with pills or insulin shots. The duration of diabetes at enrolment was based on the
difference between age of participants when first diagnosed with diabetes and age at enrolment.
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(Cantrell et al, 2010; Zhang et al, 2011); however, results from our
study along with another case-control study (Becker et al, 2013)
did not support the effect of metformin in preventing the risk of
endometrial cancer. Metformin is an oral biguanide commonly
used for the treatment of type 2 diabetes. It has recently been
demonstrated in laboratory data to possess anti-proliferative
properties that can be exploited for the prevention and treatment
of a variety of cancers. The proposed mechanism for the anti-
neoplastic effects of metformin is by activating AMP protein kinase
(AMPK) via serine/threonine kinase 11 (STK11 or LKB1). AMPK
activation inhibits cellular proliferation and mRNA translation via
mammalian target of rapamycin (mTOR) signalling, which may
contribute to the direct anti-neoplastic effects of metformin (Shaw
et al, 2005; Zakikhani et al, 2006; Williams and Brenman, 2008).
Studies have reported that metformin can reverse progestin
resistance in endometrial cancer cells by downregulating GloI
expression (Zhang et al, 2011). Metformin was also reported to
inhibit the proliferation of Ishikawa and ECC-1 endometrial cancer
cell lines by activating AMPK and subsequent inhibiting of mTOR
(Cantrell et al, 2010). Thus, metformin may not be effective for
preventing endometrial cancer, but still might be an effective part
of a cancer treatment regimen. A recent meta-analysis also found
that metformin therapy improves the survival for endometrial
cancer patients with concurrent diabetes (Zhang and Li, 2014).
Strengths of our study include the prospective design, detailed
information on exposure, central coding of cancer diagnoses,
information on obesity and inclusion of other potential con-
founders. However, several limitations deserve mention. First,
diabetes status was based on self-report. Despite high positive and
negative predictive value of self-reported diabetes in WHI, this may
result in some degree of exposure misclassification, which may
have led us to underestimate the strength of the association we
observed. Second, patients may change their diabetes status during
follow-up, which we were able to assess. They may also change
their treatment plans during the course of diabetes. Classifying
diabetes treatment based on the WHI current medication
inventory collected at baseline would not capture these treatment
changes. This kind of exposure misclassification is most likely to be
non-differential, and may bias our effect toward to the null. Third,
despite the relatively large number of participants, the statistical
power was limited for studying the association of diabetes and
endometrial cancer in sub-groups of medication treatment or
stratified by obesity status. It is possible that lack of association
after adjustment for BMI in the analyses limited to prevalent
diabetes could be due to limited statistical power, since increasing
the number of treated cases from 55–130 in the analyses that
included both prevalent and incident diabetes found a positive
association between diabetes and endometrial cancer risk even
after adjustment for BMI.
In conclusion, our results suggest that the relationship observed
in previous research between diabetes and endometrial cancer
incidence may be largely attributable to the higher body weight in
women with diabetes. Analyses that included women who
developed diabetes during follow-up suggest that diabetes confers
some modest residual risk of endometrial cancer that is
independent of body weight. Nevertheless, it is important to
appropriately adjust for body weight when further quantifying the
magnitude of the independent association between diabetes and
Table 3. Hazard ratios and 95% confidence intervals for endometrial cancer incidence associated with diabetes status and treatment of diabetes at
baseline stratified by obesity status
Body mass index o30kgm2 Body mass index X30kgm2
Exposure
Endometrial
cancer cases
Multiple-adjusted
hazard ratio
(95% confidence interval)a
Endometrial
cancer cases
Multiple-adjusted
hazard ratio
(95% confidence interval)a
Diabetes
No 713 1 448 1
Yes 18 1.10 (0.68–1.76) 53 1.17 (0.88–1.57)
Treated diabetes
No 5 0.86 (0.36–2.07) 11 1.01 (0.56–1.84)
Yes 13 1.22 (0.70–2.13) 42 1.22 (0.88–1.69)
Pill only 10 1.28 (0.68–2.40) 28 1.16 (0.78–1.71)
Insulin (alone or with oral medication) 3 1.07 (0.34–3.34) 14 1.37 (0.80–2.36)
Type of diabetic drugs in medication inventory
Untreated/drugs unknown 10 1.21 (0.65–2.27) 20 1.24 (0.79–1.95)
Metformin alone 4 2.28 (0.84–6.11) 8 1.38 (0.68–2.78)
Other oral medication alone 1 0.22 (0.03–1.60) 14 0.91 (0.53–1.56)
Insulin (alone or with oral medication) 3 1.50 (0.48–4.67) 11 1.39 (0.76–2.55)
Duration of diabetes
o6 years 8 0.96 (0.66–1.39) 22 0.94 (0.61–1.44)
X6 years 10 1.36 (0.99–1.87) 31 1.43 (0.99–2.07)
aIn multivariable models, we adjusted for age at enrolment (o55, 55–59, 60–64, 65–69, 70–74, X75), ethnicity (American Indian or Alaska Native, Asian or Pacific Islander, Black or African-
American, Hispanic/Latino, non-Hispanic white and other), education (high school or less, some college/technical training, college or some post-college and master or higher), smoking status
(never, former, current), recreational physical activity (total metabolic equivalent tasks (METs) per week:o5, 5–o10, 10–o20, 20–o30,X30), alcohol intake (non-drinker, past drinker,o1 drink
per month and current drinker—including frequency:o1 drink per month, 1 drink per month too1 drink per week, 1 too7 drinks per week,47 drinks per week), history of hormone therapy
use (none, oestrogen alone, oestrogen and progestin, mixed), parity (never pregnant, never had term, age of menarche (less than 12, 12–13, 14–15,X16 years), age at first birth (never had term
pregnant, o20, 20–29, X30 years), oral contraception use and different treatment assignments for clinical trials; and body mass index (o18.5, 18.5–24.9, 25.0–29.9 for women with
BMIo30 kgm 2; 30.0–34.9, 35.0–39.9, 440 for women with BMI X30 kgm 2).
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endometrial cancer. Our data did not support the protective effect
of metformin for endometrial cancer.
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